Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 645 (LINC00645)
- Target
- LINC00645
- Molecular classification
- Long non-coding RNA (lncRNA), Intergenic lncRNA, Competitive endogenous RNA (ceRNA)
01
Overview
Long intergenic non-protein coding RNA 645 (LINC00645) is a long non-coding RNA expressed from chromosome 14, significantly upregulated in malignant gliomas and endometrial cancers. It acts as an oncogene, promoting cell proliferation, migration, invasion, epithelial–mesenchymal transition, and maintenance of tumor stemness mainly through the miR-205-3p/ZEB1 axis. High levels are associated with poor prognosis and adverse tumor characteristics, making it a potential therapeutic target and biomarker in cancer management.
- Other names
- LINC00645long intergenic non-protein coding RNA 645
02
Mechanism of action
Competes with miR-205-3p, functioning as a ceRNA, leading to increased ZEB1 expression and promoting EMT in glioma cells. Upregulation is correlated with enhanced tumor migration, invasion, and proliferation
03
Biological functions
Regulation of epithelial–mesenchymal transition (EMT)Cell proliferationCell migration and invasionMaintenance of stemness and self-renewal in tumor stem cellsRegulation of gene expression via interaction with miRNAs
04
Disease associations
Cancer (Glioma/Glioblastoma, Endometrial cancer)Potential biomarker for poor prognosis in glioma
05
Safety considerations
Therapeutic targeting may risk effects on normal regulatory pathways of RNA metabolism and stem cell maintenance, but detailed safety profiles are unknown due to the lack of clinical targeting approaches
06
Biomarkers
LINC00645 expression level (used for prognosis in glioma and endometrial cancer)Associated with pathological grade and survival in glioma
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 645 (LINC00645).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 645 (LINC00645).